canada clinical guidance

Impetigo (antimicrobial prescribing)

A Canadian clinical summary of impetigo (antimicrobial prescribing), with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This Canadian Paediatric Society statement covers community-associated skin and soft-tissue infection in children and youth. Adult impetigo management is outside its scope.
sources for this section:CPS paediatric SSTI

Source-attributed clinical priorities

  • Confirm a superficial bacterial pattern and consider herpes, eczema, contact dermatitis and deeper infection.
  • Use hygiene, lesion care and a topical or oral strategy selected by extent, systemic features and local resistance.
  • Reassess spread or nonresponse for resistant organisms, an alternative diagnosis or a complication.
  • Localized impetigo can often be managed without systemic antibiotics when the child is otherwise well.
sources for this section:CPS paediatric SSTI

Practical assessment and management workflow

1
Confirm superficial honey-coloured crusts or bullae and assess extent, fever and recurrent disease.
2
Use hygiene, lesion care and a local treatment strategy for limited infection.
3
Reserve oral treatment for extensive, bullous or systemically concerning disease using local resistance advice.
4
Review failure for resistant bacteria, eczema, scabies or another diagnosis.
sources for this section:CPS paediatric SSTI

Safety, red flags and urgent escalation

  • Escalate widespread blistering, systemic toxicity, periorbital spread or rapidly progressive infection.
  • Keep lesions covered and avoid sharing towels while contagious.
  • Do not repeatedly use topical antibiotics because resistance and contact sensitization can develop.
sources for this section:CPS paediatric SSTI

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CPS paediatric SSTI

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CPS paediatric SSTI

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Canadian Paediatric SocietyManagement of community-associated bacterial skin and soft tissue infections in children and prevention of recurrencePosted 2026-05-26 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.